摘要
目的:探讨炎性因子在冠心病中的表达,观察通心络对粥样斑块干预作用。方法:选择急性冠状动脉综合征(ACS组)患者44例,稳定型心绞痛(SAP)患者20例,正常对照组24例,比较各组间ToLL样受体4(TLR4)、核因子-κB(NF-κB)及肿瘤坏死因子α(TNF-α)变化。将ACS组患者分为通心络亚组和辛伐他汀亚组,治疗4周后再次检测上述指标。结果:ACS患者TLR4、NF-κB、TNF-α的表达较SAP组和正常对照组显著增高(P<0.01)。通心络亚组TLR4、NF-κB和TNF-α水平降低与辛伐他汀亚组差异无统计学意义(P>0.05)。结论:通心络与辛伐他汀一样,可抑制斑块的炎症反应,增强斑块稳定性,有望成为新的稳定斑块药物。
Objective:To explore the inflammatory factors in acute coronary syndrome(ACS) ,and observe the intervention of Tongxinluo. Method.. We enrolled 44 patients with acute coronary syndrome (ACS), 20 patients with stable angina pectoris (SAP), and 24 patients with negative CAG as controls. Then we compared the TLR4, NF-k B and TNF- a levels in different groups. The patients with ACS were divided into Tongxinluo and simvasta tin subgroups, and detectd the indexes above after 4 weeks. Result: Compared with SAP and control groups, the expressions of TI.R4, NF-kB and TNF-a on peripheral blood monocytes were significantly increased in ACS group (P〈0.01). There were no significantly differences in above indexes in simvastatin and Tongxinluo subgroups (P 〉 0.05). Conclusion Tongxinluo can reduce the inflammatory reaction of artery and improve the stability of athero- sclerotic plaque, as the same as simvastatin.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2014年第9期776-778,共3页
Journal of Clinical Cardiology
基金
重庆市卫生局医学科研计划项目(No:2012-2-303)